中国药房2012，Vol.23Issue(28)：2618-2621,4.DOI:10.6039/j.issn.1001-0408.2012.28.10
CYP2C19*17基因对氯吡格雷临床疗效影响的Meta分析
Impact of CYP2C19*17 Gene Polymorphisms on Clinical Efficacy of Clopidogrel: A Meta-analysis
摘要
Abstract
OBJECTIVE: To evaluate the impact of CYP2C19*17 gene polymorphisms on the clinical efficacy of clopidogrel systematically. METHODS: The literature was searched from the following electronic databases: EMBase, PubMed, Cochrane Library, CBM and CNKI. A meta-analysis was performed with Cochrane Collaboration's Review Manager 5.1. RESULTS: A total of 5 literatures, including 6 studies (n=29 499), were included according to inclusive criteria and exclusion criteria. The Meta-analysis showed that: the incidence of cardiovascular events in CYP2C19*17 alleles carriers was significantly lower than non-carriers [RR=0.82. 95%CI(0.73, 0.93), P=0.001]; however, the incidence of bleeding events in CYP2C19*17 alleles carriers was higher than non-carriers [RR=1.20, 95%CI(1.01, 1.42), P=0.03]. CONCLUSION: After the treatment of clopidogrel, the recurrence rate of cardiovascular events in CYP2C19*17 alleles carriers is lower than non-carriers, while the incidence of bleeding events is higher than non-carriers. In conclusion, CYP2C19* 17 allele carriers should be aware of bleeding events when using clopidogrel. Genetic testing contributes to the improvement of individual rational drug use.关键词
氯吡格雷/基因多态性/CYP2C19*17/Meta分析Key words
Clopidogrel/ Gene polymorphisms/ CYP2C19*17/ Meta-analysis分类
医药卫生引用本文复制引用
谢婧,杨莉萍,刘瑶,胡欣..CYP2C19*17基因对氯吡格雷临床疗效影响的Meta分析[J].中国药房,2012,23(28):2618-2621,4.基金项目
卫生部科技教育司卫生行业科研专项课题(201002011) （201002011）
